Cargando…

ProHeart® 12, a moxidectin extended-release injectable formulation for prevention of heartworm (Dirofilaria immitis) disease in dogs in the USA for 12 months

BACKGROUND: The efficacy of an extended-release injectable moxidectin (0.5 mg/kg) suspension (ProHeart® 12) (PH 12) in preventing the development of Dirofilaria immitis in dogs for 12 months was investigated in laboratory and field studies in the USA. METHODS: In each of two laboratory studies, 20 d...

Descripción completa

Detalles Bibliográficos
Autores principales: McTier, Tom L., Kryda, Kristina, Wachowski, Martha, Mahabir, Sean, Ramsey, Deborah, Rugg, Doug, Mazaleski, Mark, Therrien, Carol, Adams, Eric, Wolff, T., Bowman, Dwight D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6660952/
https://www.ncbi.nlm.nih.gov/pubmed/31349867
http://dx.doi.org/10.1186/s13071-019-3632-3
_version_ 1783439389692526592
author McTier, Tom L.
Kryda, Kristina
Wachowski, Martha
Mahabir, Sean
Ramsey, Deborah
Rugg, Doug
Mazaleski, Mark
Therrien, Carol
Adams, Eric
Wolff, T.
Bowman, Dwight D.
author_facet McTier, Tom L.
Kryda, Kristina
Wachowski, Martha
Mahabir, Sean
Ramsey, Deborah
Rugg, Doug
Mazaleski, Mark
Therrien, Carol
Adams, Eric
Wolff, T.
Bowman, Dwight D.
author_sort McTier, Tom L.
collection PubMed
description BACKGROUND: The efficacy of an extended-release injectable moxidectin (0.5 mg/kg) suspension (ProHeart® 12) (PH 12) in preventing the development of Dirofilaria immitis in dogs for 12 months was investigated in laboratory and field studies in the USA. METHODS: In each of two laboratory studies, 20 dogs ≥ 12 months of age were randomly allocated to receive a subcutaneous injection of saline or PH 12 on Day 0 and were then inoculated with 50 D. immitis third-stage larvae (L(3)) on Day 365. All dogs were necropsied ~ 5 months post-inoculation for adult worm counts. The field efficacy study included dogs ≥ 10 months of age from 19 veterinary clinics in the USA treated with either 20 monthly doses of Heartgard® Plus (HG Plus) (296 dogs) or two doses of PH 12 (297 dogs) on Days 0 and 365. Efficacy was determined on Days 365, 480 and 605 using adult HW antigen and microfilaria testing to assess adult HW infection. RESULTS: PH 12 was 100% effective in preventing HW disease in all three of these studies. In the laboratory studies, no PH 12-treated dogs had any adult HWs, whereas all control dogs in both studies had adult HWs [geometric mean, 30.2 (range, 22–37) for Study 1 and 32.6 (22–44) for Study 2]. In the field study, all dogs treated with PH 12 tested negative for adult HW infection on all test days (Days, 365, 480 and 605), whereas four dogs receiving HG Plus (positive control) tested positive for HWs during the study (three dogs on Day 365 and one dog on Day 480). All four dogs treated with HG Plus that subsequently tested positive for HWs during the field study were from the lower Mississippi River Valley region, where HW resistance to macrocyclic lactone preventives has been confirmed to occur. PH 12 was significantly better than HG Plus in preventing heartworm disease in the field study (P = 0.0367). PH 12 was well-tolerated in both laboratory and field studies. CONCLUSIONS: A single dose of ProHeart® 12 was 100% effective in preventing heartworm disease in dogs for a full year in both laboratory and field studies.
format Online
Article
Text
id pubmed-6660952
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-66609522019-08-01 ProHeart® 12, a moxidectin extended-release injectable formulation for prevention of heartworm (Dirofilaria immitis) disease in dogs in the USA for 12 months McTier, Tom L. Kryda, Kristina Wachowski, Martha Mahabir, Sean Ramsey, Deborah Rugg, Doug Mazaleski, Mark Therrien, Carol Adams, Eric Wolff, T. Bowman, Dwight D. Parasit Vectors Research BACKGROUND: The efficacy of an extended-release injectable moxidectin (0.5 mg/kg) suspension (ProHeart® 12) (PH 12) in preventing the development of Dirofilaria immitis in dogs for 12 months was investigated in laboratory and field studies in the USA. METHODS: In each of two laboratory studies, 20 dogs ≥ 12 months of age were randomly allocated to receive a subcutaneous injection of saline or PH 12 on Day 0 and were then inoculated with 50 D. immitis third-stage larvae (L(3)) on Day 365. All dogs were necropsied ~ 5 months post-inoculation for adult worm counts. The field efficacy study included dogs ≥ 10 months of age from 19 veterinary clinics in the USA treated with either 20 monthly doses of Heartgard® Plus (HG Plus) (296 dogs) or two doses of PH 12 (297 dogs) on Days 0 and 365. Efficacy was determined on Days 365, 480 and 605 using adult HW antigen and microfilaria testing to assess adult HW infection. RESULTS: PH 12 was 100% effective in preventing HW disease in all three of these studies. In the laboratory studies, no PH 12-treated dogs had any adult HWs, whereas all control dogs in both studies had adult HWs [geometric mean, 30.2 (range, 22–37) for Study 1 and 32.6 (22–44) for Study 2]. In the field study, all dogs treated with PH 12 tested negative for adult HW infection on all test days (Days, 365, 480 and 605), whereas four dogs receiving HG Plus (positive control) tested positive for HWs during the study (three dogs on Day 365 and one dog on Day 480). All four dogs treated with HG Plus that subsequently tested positive for HWs during the field study were from the lower Mississippi River Valley region, where HW resistance to macrocyclic lactone preventives has been confirmed to occur. PH 12 was significantly better than HG Plus in preventing heartworm disease in the field study (P = 0.0367). PH 12 was well-tolerated in both laboratory and field studies. CONCLUSIONS: A single dose of ProHeart® 12 was 100% effective in preventing heartworm disease in dogs for a full year in both laboratory and field studies. BioMed Central 2019-07-26 /pmc/articles/PMC6660952/ /pubmed/31349867 http://dx.doi.org/10.1186/s13071-019-3632-3 Text en © The Author(s) 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
McTier, Tom L.
Kryda, Kristina
Wachowski, Martha
Mahabir, Sean
Ramsey, Deborah
Rugg, Doug
Mazaleski, Mark
Therrien, Carol
Adams, Eric
Wolff, T.
Bowman, Dwight D.
ProHeart® 12, a moxidectin extended-release injectable formulation for prevention of heartworm (Dirofilaria immitis) disease in dogs in the USA for 12 months
title ProHeart® 12, a moxidectin extended-release injectable formulation for prevention of heartworm (Dirofilaria immitis) disease in dogs in the USA for 12 months
title_full ProHeart® 12, a moxidectin extended-release injectable formulation for prevention of heartworm (Dirofilaria immitis) disease in dogs in the USA for 12 months
title_fullStr ProHeart® 12, a moxidectin extended-release injectable formulation for prevention of heartworm (Dirofilaria immitis) disease in dogs in the USA for 12 months
title_full_unstemmed ProHeart® 12, a moxidectin extended-release injectable formulation for prevention of heartworm (Dirofilaria immitis) disease in dogs in the USA for 12 months
title_short ProHeart® 12, a moxidectin extended-release injectable formulation for prevention of heartworm (Dirofilaria immitis) disease in dogs in the USA for 12 months
title_sort proheart® 12, a moxidectin extended-release injectable formulation for prevention of heartworm (dirofilaria immitis) disease in dogs in the usa for 12 months
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6660952/
https://www.ncbi.nlm.nih.gov/pubmed/31349867
http://dx.doi.org/10.1186/s13071-019-3632-3
work_keys_str_mv AT mctiertoml proheart12amoxidectinextendedreleaseinjectableformulationforpreventionofheartwormdirofilariaimmitisdiseaseindogsintheusafor12months
AT krydakristina proheart12amoxidectinextendedreleaseinjectableformulationforpreventionofheartwormdirofilariaimmitisdiseaseindogsintheusafor12months
AT wachowskimartha proheart12amoxidectinextendedreleaseinjectableformulationforpreventionofheartwormdirofilariaimmitisdiseaseindogsintheusafor12months
AT mahabirsean proheart12amoxidectinextendedreleaseinjectableformulationforpreventionofheartwormdirofilariaimmitisdiseaseindogsintheusafor12months
AT ramseydeborah proheart12amoxidectinextendedreleaseinjectableformulationforpreventionofheartwormdirofilariaimmitisdiseaseindogsintheusafor12months
AT ruggdoug proheart12amoxidectinextendedreleaseinjectableformulationforpreventionofheartwormdirofilariaimmitisdiseaseindogsintheusafor12months
AT mazaleskimark proheart12amoxidectinextendedreleaseinjectableformulationforpreventionofheartwormdirofilariaimmitisdiseaseindogsintheusafor12months
AT therriencarol proheart12amoxidectinextendedreleaseinjectableformulationforpreventionofheartwormdirofilariaimmitisdiseaseindogsintheusafor12months
AT adamseric proheart12amoxidectinextendedreleaseinjectableformulationforpreventionofheartwormdirofilariaimmitisdiseaseindogsintheusafor12months
AT wolfft proheart12amoxidectinextendedreleaseinjectableformulationforpreventionofheartwormdirofilariaimmitisdiseaseindogsintheusafor12months
AT bowmandwightd proheart12amoxidectinextendedreleaseinjectableformulationforpreventionofheartwormdirofilariaimmitisdiseaseindogsintheusafor12months